Page last updated: 2024-11-04

bay-k-8644

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bay-K-8644 is a synthetic compound that acts as a potent and selective activator of L-type calcium channels. Its synthesis involves a multi-step process starting with a substituted phenylalanine derivative. It has been shown to have a variety of effects, including increasing heart rate, contractility, and blood pressure. Due to its potent calcium channel activation, Bay-K-8644 has been extensively studied as a potential therapeutic agent for cardiovascular diseases. However, its use is limited by its potential side effects, including arrhythmias and vasoconstriction. Research using Bay-K-8644 has contributed significantly to understanding the role of calcium channels in various physiological processes and disease states.'

(R)-Bay-K-8644 : A methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate in which the 4-position has (R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644 [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6604881
CHEMBL ID105672
CHEBI ID131349
CHEBI ID108583
SCHEMBL ID718828
MeSH IDM0464447
PubMed CID2303
CHEMBL ID1322959
CHEBI ID34555
CHEBI ID131345
SCHEMBL ID133106
SCHEMBL ID14612812
MeSH IDM0464447

Synonyms (157)

Synonym
BIDD:PXR0106
HMS3268C15
BRD-K16695519-001-01-6
NCGC00025210-01
tocris-1546
NCGC00161392-01
bk8644
98791-67-4
r(+)-bay k 8644
CHEMBL105672 ,
CHEBI:131349
(r)-bayk8644
(+)-bay-k-8644
(r)-bay k8644
(+)-bay k8644
(+)-bayk8644
(r)-bay-k-8644
methyl (4r)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
(r)-(+)-bay k 8644
SCHEMBL718828
CS-3614
(4r)-1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester
bay k8644, (+)-
(r)-(+)-bay-k-8644
HY-15125
AKOS024456657
bay-k-8644 ((r)-(+)-)
CHEBI:108583
A916225
DTXSID00913080
bay-k-8644 (r)-(+)-
bay-k-8644-(+/-)
MS-25574
YDA79167
(4r)-1,4-dihydro-2,6-dimethyl-5-nitro-4-[(2-trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester
EN300-18543981
zflwdhhvrrzmei-cybmujfwsa-n
bay-k-8644(r)-(+)-
E98637
CBIOL_001744
(+/-)-bay k8644
MLS002153190
smr001230679
MLS001148586
bdbm50035800
(s)-2,6-dimethyl-5-nitro-4-(2-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid methyl ester
HMS3268C13
BRD-A05457250-001-03-5
(+/-)-bay k 8644
smr000058424
MLS000028858 ,
EU-0100186
(+/-)-bay k8644, calcium channel agonist
BIO1_000030
BIO1_001008
BIO1_000519
BSPBIO_001578
HSCI1_000381
bayk8644
bay-k-8644
71145-03-4
bay k 8644
NCGC00025209-05
NCGC00025209-04
c16h15f3n2o4
3-pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, methyl ester
LOPAC0_000186
NCGC00025209-06
NCGC00025209-03
(?)-bay k 8644
NCGC00025209-02
bay k8644
bayk 8644
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
gtpl2511
methyl 2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylate
NCGC00015124-03
1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)-phenyl]-
HMS1989O20
B-112
3-pyridine carboxylic acid methyl ester
( inverted question mark)-bay k 8644
NCGC00015124-08
93468-89-4
HMS1791O20
(+/-)-bay-k-8644
chebi:34555
ncg-c00025209-02
CHEBI:131345
(4r)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid methyl ester
A837092
HMS3260F13
CCG-204281
HMS2232B12
HMS2231A11
NCGC00015124-06
NCGC00015124-07
NCGC00015124-04
NCGC00015124-05
STL213543
LP00186
AKOS015858973
3-pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-, methyl ester
AM20080536
S7924
HMS3370M19
HMS3371N20
CA-410
SCHEMBL133106
NCGC00260871-01
(y)-bay k 8644
tox21_500186
CHEMBL1322959
1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid, methyl ester
SCHEMBL14612812
bay k 8644, (+/-)-
HMS3402O20
OPERA_ID_789
mfcd00036697
SR-01000075305-1
SR-01000075305-3
sr-01000075305
zflwdhhvrrzmei-uhfffaoysa-n
bay-r 4407
bay-r 5417
3-pyridinecarboxylic acid,1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-,methyl ester
FT-0742944
BCP24795
bay-k-8644 ((r)-(+)-); r-4407; ni-105; (+)-bay-k-8644;r(+)bay k 8644
bayk 8644; bayk8644; bayk-8644;bay k8644;bay k 8644
BCP15942
BCP23924
Q4874027
HB1209
E77139
HMS3676J07
AS-16745
( inverted exclamation marka)-bay-k-8644
sq 28,873
HMS3412J07
DTXSID301017346
methyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylate
EX-A4933
bay k 8644 racemate
BRD-A05457250-001-04-3
(+/-)-bayk8644
SDCCGSBI-0050174.P002
EX-A3340
NCGC00015124-13
HMS3886L19
1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl)pyridine-3-carboxylic acid methyl ester
HY-10588
BB162780
CS-0002659
EN300-746258
Z1213715450
3-pyridinecarboxylic acid,1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-, methylester, (a+/-)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Nicardipine increased significantly the AUC and Cmax of oral propranolol (1."( Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.
Dupont, AG; Massart, DL; Schoors, DF; Vercruysse, I, 1993
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"The haemodynamic effects of the Ca-agonist BAY K 8644 alone and in combination with the selective beta-I-adrenoceptor agonist dobutamine were studied in the isolated rabbit heart."( Pharmacodynamics of BAY K 8644 alone and in combination with dobutamine in the isolated rabbit heart.
Pedersen, OL; Sørensen, EV, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
" Nifedipine also significantly increased the AUC and Cmax of oral propranolol (15 mg/kg), whereas with BAY-K-8644 there was only a slight increase in the bioavailability of oral propranolol (15 mg/kg)."( Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.
Dupont, AG; Massart, DL; Schoors, DF; Vercruysse, I, 1993
)
0.72
"05), mimicking the effect of an apparent decrease in bioavailability of endogenous NO."( Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles.
Gerzanich, V; Simard, JM; West, GA; Zhang, F, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
", dose-response curves for U46619 and U44069 were shifted to the right in a parallel manner."( Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban.
Babycos, CR; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD; Ragheb, MS, 1992
)
0.28
"Effects of Bay K 8644, partial depolarization with high potassium, and nifedipine on the dose-response curves of the rat vas deferens to norepinephrine, methacholine and KCI were investigated in HEPES-buffered physiological salt solution (PSS) with or without 20 mM sodium bicarbonate."( Bicarbonate-dependent action of Bay K 8644 in the smooth muscle of the rat vas deferens.
Gomi, Y; Suzuki, N, 1990
)
0.28
" Treatment with pertussis toxin caused the DBP dose-response curve to SRTX-b to be displaced to the right."( Effects of nifedipine, BAY K 8644, and pertussis toxin on pressor response to sarafotoxin-b in pithed rats.
Tabrizchi, R; Triggle, CR, 1990
)
0.28
" Sixty percent D2O also depressed a calcium contraction dose-response curve by approximately 25%."( Deuterium oxide reduces agonist and depolarization-induced contraction of rat aortic rings.
Liepins, A; McWilliam, TM; Rankin, AJ, 1990
)
0.28
"0 mM: maximum DP achieved with each agonist was significantly less and the dose-response curves to each agonist were shifted leftward in CMH versus control hearts."( Diminished tolerance of prehypertrophic, cardiomyopathic Syrian hamster hearts to Ca2+ stresses.
Hano, O; Lakatta, EG, 1991
)
0.28
"The dose-response effects of BAY K 8644 and nifedipine on diaphragmatic contractility were assessed in vitro."( Multiple effects of BAY K 8644 and nifedipine on isolated diaphragmatic fibers in vitro.
Aubier, M; Pavlovic, D; Viires, N, 1991
)
0.28
" Nifedipine (3 X 10(-7) M) produced a parallel shift to the right of the dose-response curve to BAY-K-8644, whereas 5 X 10(-6)M verapamil markedly reduced the responses evoked by all concentrations of this drug."( The effects of BAY-K-8644 on the contraction of cat middle cerebral and femoral arteries.
Marin, J; Reviriego, J; Salaices, M; Sanchez-Ferrer, CF, 1985
)
0.84
" In the isolated rat mesenteric artery, perfused with a depolarizing solution, vasoconstrictor Ca2+ dose-response curves are shifted to the right by nifedipine."( In vitro comparative studies of the calcium-entry activators YC-170, CGP 28392, and BAY K 8644.
Criscione, L; Meier, M; Rogg, H; Truog, A, 1985
)
0.27
" BAY K 8644, in either potassium buffer, induced a statistically significant shift to the left in the norepinephrine dose-response curve."( The facilitative actions of Bay K 8644 on norepinephrine and KCl-induced contractures of rabbit aortic rings.
Babich, M; Piascik, MT, 1986
)
0.27
" Dose-response curves to K+ show that following differentiation, cells become more sensitive, releasing transmitter at lower K+ concentrations."( Nerve growth factor modulates the drug sensitivity of neurotransmitter release from PC-12 cells.
Kongsamut, S; Miller, RJ, 1986
)
0.27
" The dose-response curve for BAY K 8644 was established in 5 mM K+-containing medium and for 30 min exposure to 45Ca."( BAY K 8644-induced enhancement of 45Ca uptake by rabbit aortic rings.
Anderson, CL; Janis, RA; Scriabine, A,
)
0.13
" When the effect of nifedipine on the dose-response curve for Bay k 8644 was determined in WKY femoral artery, there was a similar extent of rightward displacement of the dose-response curve to that seen in SHR."( Contractile effects of Bay k 8644, a dihydropyridine calcium agonist, on isolated femoral arteries from spontaneously hypertensive rats.
Aoki, K; Asano, M; Matsuda, T, 1986
)
0.27
" The dose-response curves for VIP- and PHI-stimulated cAMP accumulation were superimposable on those for PRL secretion."( Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+.
Bjøro, T; Gautvik, KM; Gordeladze, J; Haug, E; Iversen, JG; Ostberg, BC; Sand, O; Torjesen, PA, 1987
)
0.27
" The effect of ANP on the dose-response curve of aldosterone stimulated by ANG II, ACTH, and potassium on isolated rat adrenal glomerulosa cells was studied."( Role of calcium in effects of atrial natriuretic peptide on aldosterone production in adrenal glomerulosa cells.
Chartier, L; Schiffrin, EL, 1987
)
0.27
" However, in rings with denuded endothelium, pretreatment with (-)-R202-791 resulted in a rightward shift of the dose-response curve to (+)-S202-791, and a depression of the maximal contraction compared with controls."( A possible role for the endothelium in porcine coronary smooth muscle responses to dihydropyridine calcium channel modulators.
Baik, YH; Koch, WJ; Schwartz, A; Williams, JS, 1987
)
0.27
" Bay K 8644 caused a leftward shift of the dose-response curve of the potassium-induced decrease in renin release."( Inhibitory effects of calcium channel agonists on renin release from rat kidney cortical slices.
Matsumura, Y; Morimoto, S; Sasaki, Y; Shinyama, H; Uriu, T, 1987
)
0.27
" Bay K 8644 (10(-8) M) markedly potentiated B-HT-958-mediated vasoconstrictor responses with a leftward shift and an increase in the maximum response of the logarithmic dose-response curve."( Sensitivity of alpha-adrenoceptor agonists to the calcium channel activator, Bay K 8644, in canine saphenous vein.
Eskinder, H; Gross, GJ, 1987
)
0.27
" Higher concentrations of these antagonists shifted the Ca2+ dose-response curve to the right."( Adrenergic-cholinergic interactions in left atria. II. Comparison of the antagonism of inotropic responses to alpha- and beta-adrenoceptor stimulation and BAY K 8644 by carbachol, D-600, and nifedipine.
MacLeod, KM, 1987
)
0.27
" The dose-response curve of nifedipine was shifted parallel to the right by the infusion of Bay K 8644 and the dose-ratio was the greatest of the 4 drugs."( Differential antagonism by Bay K 8644 of vasodilator effects of nifedipine, diltiazem, nicorandil and nitroglycerin in dog femoral circulation.
Ishii, K; Sato, Y; Taira, N, 1988
)
0.27
" When the effects of an elevation in the level of extracellular K+ on the contractile responses to BAY were determined in SHR and WKY rat femoral arteries, dose-response curves for BAY were not significantly different between the SHR and WKY rats."( Increased responsiveness to calcium agonist BAY k 8644 and calcium antagonist nifedipine in femoral arteries of spontaneously hypertensive rats.
Aoki, K; Asano, M, 1987
)
0.27
"1 microM) to isolated hearts, or when given intravenously (2 mg kg-1 body weight 1 h before the animals were killed), anipamil displaced the dose-response curves for the positive inotropic effect of (0."( The Ca2+ -antagonist and binding properties of the phenylalkylamine, anipamil.
Dillon, JS; Nayler, WG, 1988
)
0.27
" The purpose of the present experiments has been to investigate a possible similar dose-response curve with a calcium channel activator, Bay k 8644."( Biphasic dose-response relationship observed with Bay k 8644 on atrioventricular nodal conduction inhibited by verapamil.
Aupetit, JF; Faucon, G; Lançon, JP; Lang, J; Timour, Q, 1988
)
0.27
" The 45Ca++ uptake dose-response curves and the half maximal effects of the three agonists were over the same range of concentrations as their inhibition of [3H]nitrendipine binding to rat ventricular receptor membrane preparations."( Calcium uptake studies of 1,4-dihydropyridine agonists into rabbit aortic smooth muscle cells in culture.
Panzer-Knodle, S; Papaioannou, S; Yang, PC, 1989
)
0.28
" In contrast, isoproterenol shifted the entire dose-response curve for nifedipine to the right."( Interaction between isoproterenol and dihydropyridines in heart cells.
Briand, V; Laurent, S; Schmitt, H, 1989
)
0.28
"0 nM) on dose-response curves to noradrenaline, histamine, calcium (Ca2+) and potassium (K+) in ring preparations of rabbit basilar artery and central ear artery."( The selective potentiation of noradrenaline-induced tone by Bay K 8644 in the rabbit basilar artery.
Bevan, JA; Dowd, AL; Germann, P; Laher, I, 1989
)
0.28
" Chlordiazepoxide shifted the dose-response curves for TRH stimulation of PRL release and synthesis to the right, and did not change PRL release alone."( Pituitary thyrotropin-releasing hormone (TRH) receptors: effects of TRH, drugs mimicking TRH action, and chlordiazepoxide.
Hinkle, PM; Shanshala, ED, 1989
)
0.28
"When the dose-response curve of adrenocorticotropin (ACTH)-induced aldosterone secretion is compared to that of ACTH-induced intracellular cAMP, the ED50 for intracellular cAMP is more than 10 times as high as that for aldosterone production."( Role of calcium and cAMP in the action of adrenocorticotropin on aldosterone secretion.
Kojima, I; Kojima, K; Rasmussen, H, 1985
)
0.27
" Only a leftward shift of the dose-response curves was observed, which was most pronounced for (-)-phenylephrine and Sgd 101/75."( Interactions between the putative calcium entry promotor Bay k 8644 and pressor responses produced by alpha 1- and alpha 2-adrenoceptor agonists in the pithed normotensive rat.
de Jonge, A; Mathy, MJ; Thoolen, MJ; Timmermans, PB; van Heiningen, PN; van Zwieten, PA; Wilffert, B, 1984
)
0.27
" Dose-response curves for the physiological effects of the drugs are observed over the same range of concentrations as their inhibition of [3H]nitrendipine binding to its receptor."( Activation of the voltage-dependent Ca2+ channel in rat heart cells by dihydropyridine derivatives.
Lazdunski, M; Méaux, JP; Renaud, JF; Romey, G; Schmid, A, 1984
)
0.27
" Nifedipine released during Days 11-14 elicited an inverted U-shaped dose-response curve in the VDI with a peak increase of 30."( Calcium entry blockers stimulate vasoproliferation on the chick chorioallantoic membrane.
Dusseau, J; Hutchins, PM, 1993
)
0.29
" A good parallelism exits between the dose-response curves for PGE2 inhibition of ICa in isolated chemoreceptor cells and high extracellular [K+]- or hypoxia-evoked release of [3H]CA from the whole CB."( Inhibition of [3H]catecholamine release and Ca2+ currents by prostaglandin E2 in rabbit carotid body chemoreceptor cells.
Almaraz, L; Gómez-Niño, A; González, C; López-López, JR, 1994
)
0.29
"Pressor dose-response curves to endothelin 1 (0."( Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis.
Cailmail, S; Gaudin, C; Hartleb, M; Lebrec, D; Moreau, R, 1994
)
0.29
"0 mg/kg) produced dose-dependent rightward shifts of the (+/-)BAY k 8644 dose-response curve."( Modification of the behavioral effects of (+/-)BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys.
Barrett, JE; Rosenzweig-Lipson, S, 1995
)
0.29
") were found to enhance nicotine-induced antinociception by shifting its dose-response curve to the left."( Involvement of calcium and L-type channels in nicotine-induced antinociception.
Damaj, MI; Martin, BR; Welch, SP, 1993
)
0.29
" These data show a close temporal and dose-response relationship between Ca2+ entry via L-type voltage-sensitive Ca2+ channels and Ins(1,4,5)P3 formation following depolarization with K+, indicating that Ca2+ influx can activate phospholipase C in SH-SY5Y cells."( Activation of phospholipase C in SH-SY5Y neuroblastoma cells by potassium-induced calcium entry.
Lambert, DG; Smart, D; Wandless, A, 1995
)
0.29
" Dose-response studies were performed using previously reported inhibitors of cytosolic calcium oscillation mechanisms."( The mechanisms underlying Bay K 8644-stimulated phasic myometrial contractions.
Chien, EK; Phillippe, M; Saunders, T,
)
0.13
" The results indicate that nimodipine and BayK 8644 shifted the dose-response curve for cocaine's reinforcing action to the right and left, respectively."( Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca2+ channel modulators.
Kuzmin, A; Ramsey, NF; Semenova, S; Van Ree, JM; Zvartau, EE, 1996
)
0.29
"When uterine muscle was exposed to full-thickness fetal membranes (amnion-chorion with attached decidua) or to the intact fetal components (chorion-amnion) or to chorion alone, the Bay K 8644 dose-response curve was significantly shifted to the right."( Human fetal membranes inhibit calcium L-channel activated uterine contractions.
Collins, PL; Idriss, E; Kulp, TM; Moore, JJ, 1996
)
0.29
" BAY K 8644 produced a larger increase in sensitivity in adrenal capsule preparations from pregnant than from nonpregnant rats, leading to superposition of the two dose-response curves to K+."( Effects of dihydropyridines on aldosterone secretion in adrenal capsule preparations from pregnant rats.
Brochu, M; Jodoin, S; Picard, S; St-Louis, J, 1997
)
0.3
" Pretreatment with nifedipine (10-30 mg/kg) produced dose-dependent rightward shifts of the (+/-)-Bay K 8644 dose-response curve."( Effects of dihydropyridine Ca2+ channel blockers on the discriminative stimulus and the motor impairing effects of (+/-)-Bay K 8644.
Cohen, C; Perrault, G; Sanger, DJ, 1997
)
0.3
" However, the inhibition of the combined CPA and CCh response was reduced and the dose-response curve of SIN-1 shifted to the right."( Involvement of intracellular Ca2+ stores in inhibitory effects of NO donor SIN-1 and cGMP.
Allescher, HD; Franck, H; Puschmann, A; Schusdziarra, V; Storr, M, 1998
)
0.3
" Hypothermia shifted the dose-response curves to the right for the negative chronotropic and inotropic effects of verapamil and for the negative chronotropic and positive inotropic effects of zatebradine, but not for the negative chronotropic and positive inotropic effects of E-4031."( Effects of low temperature on the chronotropic and inotropic responses to zatebradine, E-4031 and verapamil in isolated perfused dog atria.
Chiba, S; Furukawa, Y; Hoyano, Y; Kasama, M; Oguchi, T, 1998
)
0.3
") was administered prior to a cumulative DZP or PCP dose-response determination."( Modulation of the ethanol-like discriminative stimulus effects of diazepam and phencyclidine by L-type voltage-gated calcium-channel ligands in rats.
Grant, KA; Green-Jordan, K, 2000
)
0.31
" The dose-response curve of insulin secretion showed a markedly reduced maximum response, but almost normal glucose sensitivity in NSY islets."( Insulin secretion to glucose as well as nonglucose stimuli is impaired in spontaneously diabetic Nagoya-Shibata-Yasuda mice.
Babaya, N; Hamada, Y; Ikegami, H; Kawaguchi, Y; Nojima, K; Ogihara, T; Shibata, M; Ueda, H; Yamada, K; Yamato, E, 2001
)
0.31
" Isolated right ventricular myocardial strips were used to generate dose-response curves to isoproterenol, forskolin, and Bay K 8644."( Altered inotropic reactivity in diabetic rabbit right ventricular myocardium.
Lee, JR; Lin, BK; Reigel, CE; Tenner, TE; Zhang, XJ, 2004
)
0.32
" Dose-response curves to benzodiazepines on peak [Ca2+]i and shortening were not affected by pretreatment with Bay K 8644 (0."( Effects of L-type Ca2+ channel modulation on direct myocardial effects of diazepam and midazolam in adult rat ventricular myocytes.
Damron, DS; Kanaya, N; Murray, PA, 2006
)
0.33
" Dose-response analyses revealed a structure-activity relationship where the larger the side-chain the higher the inhibitory potency."( Functional inhibition of intestinal and uterine muscles by non-permeant triphenylethylene derivatives.
Díaz, M; García Marrero, B; Gómez, T; Marrero-Alonso, J, 2006
)
0.33
" The dose-response curves for high K(+), ACh, and ET-1 were shifted to the left, so that at some lower doses of these agents the increased perfusion pressure was greater in coronary arteries obtained from diabetic rats than in those from control rats."( Effect of long-term streptozotocin-induced diabetes on coronary vasoconstriction in isolated perfused rat heart.
Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y, 2008
)
0.35
" The cardiomyocytes showed a chronotropic dose-response (0."( Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells.
Atan, S; Chung, YY; Dusting, G; Iskandar, F; Mehta, A; Ng, A; Shim, W; Sun, W; Wei, H; Wong, P, 2011
)
0.37
" Moreover, fasudil pretreatment shifted norepinephrine dose-response curves to the right more in WKY than in SHR."( Ca2+ sensitization and Ca2+ entry in the control of blood pressure and adrenergic vasoconstriction in conscious Wistar-Kyoto and spontaneously hypertensive rats.
Behuliak, M; Bencze, M; Karen, P; Kuneš, J; Líšková, S; Petrová, M; Pintérová, M; Vaněčková, I; Zicha, J, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylateA pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.
dihydropyridine
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.92450.140911.194039.8107AID2451
LuciferasePhotinus pyralis (common eastern firefly)Potency3.98110.007215.758889.3584AID411
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency29.88160.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency6.30960.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.12590.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.15850.00636.904339.8107AID883
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.15850.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.02240.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID2323
glp-1 receptor, partialHomo sapiens (human)Potency11.90470.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency23.44320.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency21.91900.180013.557439.8107AID1460
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency20.07930.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.30880.001530.607315,848.9004AID1224819; AID1224820; AID1224821
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency25.11890.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency40.87070.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency7.94330.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
DNA polymerase betaHomo sapiens (human)Potency100.00000.022421.010289.1251AID485314
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency18.35640.004611.374133.4983AID624296
M-phase phosphoprotein 8Homo sapiens (human)Potency39.81070.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency25.11890.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency0.00450.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.63100.015812.3113615.5000AID1461
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624288
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency44.96473.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki2.77000.00000.930610.0000AID34564; AID34862
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.78500.00011.20929.9700AID32336
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki6.20000.00030.91969.0000AID33356
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki35.10000.00021.494010.0000AID32882; AID33788
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Mus musculus (house mouse)EC50 (µMol)20.80000.40002.771410.0000AID482149
Transient receptor potential cation channel subfamily A member 1Mus musculus (house mouse)EC50 (µMol)32.70000.40002.771410.0000AID482149
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)Concentration3.00003.00003.00003.0000AID171281
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)Concentration3.00003.00003.00003.0000AID171281
Voltage-dependent L-type calcium channel subunit alpha-1SRattus norvegicus (Norway rat)Concentration3.00003.00003.00003.0000AID171281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (152)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID32882Displacement of [3H]CGS-21680 from Adenosine A2A receptor of rat striatal membrane at 10e-4 uM1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.
AID34862Displacement of [125 I]AB-MECA from Adenosine A3 receptor expressed in HEK cells1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.
AID32336Displacement of [3H]-R-PIA from adenosine A1 receptor of rat brain membrane1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.
AID31706Displacement of [3H](R)-PIA binding to Adenosine A1 receptor in rat brain membranes1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID33497Inhibition of adenylyl cyclase by A3 agonist IB-MECA(10e-7M) in CHO cell membranes expressing rat Adenosine A3 receptor1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID33356Binding affinity against rat Adenosine A3 receptor from CHO cells1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID232706Selectivity ratio of Ki for rat A3 and human A3 adenosine receptors1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID232705Selectivity ratio of Ki for rat A2A and A3 adenosine receptors1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID232704Selectivity ratio of Ki for rat A1 and A3 adenosine receptor1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID34564Displacement of [125]AB-MECA binding to human Adenosine A3 receptor expressed in HEK cells1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID33788Displacement of [3H]-CGS- 21680 binding to Adenosine A2A receptor in rat striatal membranes1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID482149Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID33496Inhibition of adenylyl cyclase by A3 agonist IB-MECA(10e-6M) in CHO cell membranes expressing rat Adenosine A3 receptor1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID165718Vasoconstrictor effect at a concentration of 3 x 10e-9 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID690062Vasodilatory activity in human vena saphena magna assessed as reduction in phenylephrine-induced smooth muscle contraction at 0.1 uM2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID165708Vasoconstrictor effect at a concentration of 10e-6 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID514306Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as induction of rhodopsin expression at 3 uM2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID690136Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 25% repolarized cardiac action potential duration time at 10'-7 M by microelectrode technique relative to untreated control (Rvb = 84 to 104 APD25 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690132Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 50% repolarized cardiac action potential duration time at 10'-7 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690129Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 50% repolarized cardiac action potential duration time at 10'-4 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690131Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 50% repolarized cardiac action potential duration time at 10'-6 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690059Ionotropic effect in guinea pig right ventricle papillary muscles assessed as contraction force at 10'-7 M by force transduction assay relative to untreated control (Rvb = 100%)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID228679Solvation energy1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state.
AID165711Vasoconstrictor effect at a concentration of 10e-8 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID690133Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 25% repolarized cardiac action potential duration time at 10'-4 M by microelectrode technique relative to untreated control (Rvb = 84 to 104 APD25 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID73037Tested for 45 [Ca2+] uptake in rat pituitary growth hormone3 (GH3) cells1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Discovery and synthesis of methyl 2,5-dimethyl-4-[2- (phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator.
AID690141Ionotropic effect in guinea pig right ventricle papillary muscles assessed as contraction force at 10'-4 M by force transduction assay relative to untreated control (Rvb = 100%)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID165715Vasoconstrictor effect at a concentration of 3 x 10e-8 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID165713Vasoconstrictor effect at a concentration of 10e-9 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID324369Induction of light chain 3-GFP level in human H4 cells at 7.0 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID79696Compound was tested for calcium channel agonistic activity, causing a 50% increase of the maximum contractile response on guinea pig left atrium.1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
AID690130Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 50% repolarized cardiac action potential duration time at 10'-5 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690137Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 10% repolarized cardiac action potential duration time at 10'-4 M by microelectrode technique relative to untreated control (Rvb = 37 to 47 APD10 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID175332Capacity to increase [Ca2+] entry into the vascular smooth muscle was evaluated on rat aorta strips partially depolarized with 10 mM K2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties.
AID165712Vasoconstrictor effect at a concentration of 10e-8 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID175405Compound evaluated for reducing diastolic blood pressure normotensive rats.1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID690142Ionotropic effect in guinea pig right ventricle papillary muscles assessed as contraction force at 10'-5 M by force transduction assay relative to untreated control (Rvb = 100%)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID513635Induction of autophagy in Atg positive human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID165710Vasoconstrictor effect at a concentration of 10e-7 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID324576Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID690126Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 90% repolarized cardiac action potential duration time at 10'-5 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID513629Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID513633Induction of autophagy in Atg deficient mouse MFF expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID76230In vitro calcium channel modulating activity in guinea pig ileum longitudinal smooth muscle(GPILSM)2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro- 2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers.
AID192054Compound evaluated for reducing systolic blood pressure in normotensive rats (iv, 100 ug/kg )1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID324421Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 7.0 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID167371Maximum contractile force in rabbit aorta strips1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID95740Evaluated for the free energies of binding (delta G) (in the resting state (rs) of voltage-gated L-type [Ca2+] channel (VGCCs))1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state.
AID690135Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 25% repolarized cardiac action potential duration time at 10'-6 M by microelectrode technique relative to untreated control (Rvb = 84 to 104 APD25 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID513645Induction of autophagy in african green monkey COS7 cells expressing PLC-epsilon assessed as calpain activation at 2.5 uM after 30 mins by immunoblotting analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID186242Capacity to increase [Ca2+] entry into the vascular smooth muscle was evaluated on rat aorta strips partially depolarized with 10 mM K+ relative to 50 mM KCl2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties.
AID95741Free energy of binding (delta G) for inactivated state (is) of voltage-gated L-type [Ca2+] channel(VGCCs)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state.
AID690134Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 25% repolarized cardiac action potential duration time at 10'-5 M by microelectrode technique relative to untreated control (Rvb = 84 to 104 APD25 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID513648Induction of autophagy in human SK-N-SH cells assessed as inhibition of Bay K8644-induced calpain activation2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID95739Difference in free energies of binding (delta G) in the Resting state (rs) and inactivated state (is) of voltage-gated L-type [Ca2+] channel(VGCCs)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state.
AID513626Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID690063Vasodilatory activity in human vena saphena magna assessed as relaxation of phenylephrine-induced smooth muscle contraction at 10'-7 to 10'-4 M2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID514308Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as induction of rhodopsin expression at 1 uM2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID513627Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID690127Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 90% repolarized cardiac action potential duration time at 10'-6 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690139Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 10% repolarized cardiac action potential duration time at 10'-6 M by microelectrode technique relative to untreated control (Rvb = 37 to 47 APD10 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690058Ionotropic effect in guinea pig right ventricle papillary muscles assessed as contraction force at 10'-6 M by force transduction assay relative to untreated control (Rvb = 100%)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID175885Positive inotropic activity on rat papillary muscle electrically stimulated by unipolar square wave pulses2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties.
AID482149Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID324577Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID165716Vasoconstrictor effect at a concentration of 3 x 10e-8 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID165709Vasoconstrictor effect at a concentration of 10e-7 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID175402Effect (iv, 100 ug/kg) on diastolic blood pressure in anesthetized normotensive rat1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID324473Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 7.0 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID95593Effect on L-type [Ca2+] channels of rat RIN-m5F insulinoma cells in 10 mM Ba2+, -60 mV holding potential at 3 uM, -20 mV2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties.
AID513628Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID690128Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 90% repolarized cardiac action potential duration time at 10'-7 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID165717Vasoconstrictor effect at a concentration of 3 x 10e-9 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID165444Compound was evaluated for contraction on Electrically driven Rabbit left atria. at 10e-7 M1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID74023Tested for the force increase in guinea pig atria1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Discovery and synthesis of methyl 2,5-dimethyl-4-[2- (phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator.
AID690125Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 90% repolarized cardiac action potential duration time at 10'-4 M by microelectrode technique relative to untreated control (Rvb = 132 to 176 APD50 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID79705Calcium channel agonist activity in guinea pig left atrium (GPLA) at 10e-7 M1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers.
AID324525Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 7.0 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID171281Concentration required to reduce rate of increase in L-type current in rat RIN-m5F insulinoma cells1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Synthesis and voltage-clamp studies of methyl 1,4-dihydro-2, 6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate racemates and enantiomers and of their benzofuroxanyl analogues.
AID690140Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 10% repolarized cardiac action potential duration time at 10'-7 M by microelectrode technique relative to untreated control (Rvb = 37 to 47 APD10 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID78070Tested for the force value required to increase developed tension to 50% of the isoprenaline maximum at 10 uM1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Discovery and synthesis of methyl 2,5-dimethyl-4-[2- (phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator.
AID690060Vasodilatory activity in human vena saphena magna assessed as reduction in phenylephrine-induced smooth muscle contraction at 100 uM relative to baseline contraction2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID175406Compound evaluated for reducing systolic blood pressure in normotensive rats (iv, 100 ug/kg )1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID79046Calcium channel agonist activity in guinea pig ileum longitudinal smooth muscle (GPILSM) at 10e-7 M1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID165714Vasoconstrictor effect at a concentration of 10e-9 M using partially depolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID324578Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID192050Effect (iv, 100 ug/kg) on systolic blood pressure in anesthetized normotensive rat1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID73045Tested for the 50% of the maximal [Ca2+] uptake produced by Bay K 8644 at 1 uM in rats1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Discovery and synthesis of methyl 2,5-dimethyl-4-[2- (phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator.
AID165443Compound was evaluated for contraction on Electrically driven Rabbit left atria. at 10e-6 M1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID165707Vasoconstrictor effect at a concentration of 10e-6 M using nondepolarized isolated rings from rabbit.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
AID165445Compound was evaluated for contraction on Electrically driven Rabbit left atria. at 10e-8 M1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
AID690138Ionotropic effect in guinea pig ventricle papillary muscles assessed as lengthening of 10% repolarized cardiac action potential duration time at 10'-5 M by microelectrode technique relative to untreated control (Rvb = 37 to 47 APD10 ms)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID1256896Induction of rat beta cell proliferation after 3 days relative to control2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Small molecules that promote regenerative repair for pancreatic and cardiovascular health.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346650Human Cav1.3 (Voltage-gated calcium channels)2000Cell, Jul-07, Volume: 102, Issue:1
Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels.
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)1994FEBS letters, May-09, Volume: 344, Issue:1
Calcium currents recorded from a neuronal alpha 1C L-type calcium channel in Xenopus oocytes.
AID1346714Mouse Cav1.1 (Voltage-gated calcium channels)1987The Journal of physiology, Dec, Volume: 393Calcium currents, charge movement and dihydropyridine binding in fast- and slow-twitch muscles of rat and rabbit.
AID1346714Mouse Cav1.1 (Voltage-gated calcium channels)1990Reviews of physiology, biochemistry and pharmacology, , Volume: 114Molecular properties of calcium channels.
AID1346650Human Cav1.3 (Voltage-gated calcium channels)2001The Journal of biological chemistry, Jun-22, Volume: 276, Issue:25
alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages.
AID1346660Rat Cav1.3 (Voltage-gated calcium channels)2001The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-15, Volume: 21, Issue:16
Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,469)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990658 (26.65)18.7374
1990's1235 (50.02)18.2507
2000's403 (16.32)29.6817
2010's139 (5.63)24.3611
2020's34 (1.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.75 (24.57)
Research Supply Index7.85 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index35.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Reviews27 (1.06%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
Other2,528 (98.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]